KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Accumulated Expenses (2016 - 2025)

Pacific Biosciences Of California has reported Accumulated Expenses over the past 15 years, most recently at $33.6 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $33.6 million for Q4 2025, up 48.91% from a year ago — trailing twelve months through Dec 2025 was $33.6 million (up 48.91% YoY), and the annual figure for FY2025 was $33.6 million, up 48.91%.
  • Accumulated Expenses for Q4 2025 was $33.6 million at Pacific Biosciences Of California, up from $29.2 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PACB hit a ceiling of $45.7 million in Q4 2023 and a floor of $14.7 million in Q1 2021.
  • Median Accumulated Expenses over the past 5 years was $25.2 million (2022), compared with a mean of $26.7 million.
  • Biggest five-year swings in Accumulated Expenses: soared 109.0% in 2021 and later plummeted 50.57% in 2024.
  • Pacific Biosciences Of California's Accumulated Expenses stood at $36.3 million in 2021, then fell by 10.11% to $32.6 million in 2022, then skyrocketed by 40.23% to $45.7 million in 2023, then plummeted by 50.57% to $22.6 million in 2024, then skyrocketed by 48.91% to $33.6 million in 2025.
  • The last three reported values for Accumulated Expenses were $33.6 million (Q4 2025), $29.2 million (Q3 2025), and $26.5 million (Q2 2025) per Business Quant data.